Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024

5/22/24 8:13:02 AM ET

$AVDL

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AVDL alert in real time by email

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ –

– Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care –

DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.

Get the next $AVDL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVDL

Date	Price Target	Rating	Analyst
6/12/2024	$27.00	Buy	Rodman & Renshaw
3/5/2024	$27.00 → $29.00	Outperform	Oppenheimer
3/5/2024	$21.00 → $25.00	Buy	H.C. Wainwright
3/5/2024	$20.00 → $22.00	Buy	Needham
2/6/2024	$21.00	Buy	UBS
11/30/2022	$6.50 → $11.00	Hold → Buy	Jefferies
8/10/2022	$6.00 → $8.00	Buy → Hold	Jefferies
7/28/2022	$15.50 → $12.00	Buy	Craig Hallum

More analyst ratings

$AVDL
Financials

Live finance-specific insights

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcas
11/4/24 8:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care
Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are advised
8/1/24 8:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and anno
5/8/24 7:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care

$AVDL
Press Releases

Fastest customizable press release news feed in the world

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company focused on transforming medicines to transform liv
11/13/24 8:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care
Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results
-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter -- -- Received FDA approval for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years and older with narcolepsy, granted ODE through October 16, 2031 -- -- LUMRYZ approval upheld by court in suit brought by Jazz regarding FDA's determination that LUMRYZ is clinically superior to twice-nightly oxybate products -- -- Progressed Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Nov. 12
11/12/24 7:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care
Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcas
11/4/24 8:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care

Avadel Pharmaceuticals to Join Russell 3000® Index
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit
6/27/24 4:05:00 PM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to our board of directors," said Geoffrey M. Glass, Avadel Chairman of the Board. "Dr. Amin's extensive experience in identifying, developing, and commercializing new medicines for d
5/21/24 7:00:00 AM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care
Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs. "We are pleased to welcome Brandi to the Avadel team as our Senior Vice President, Corporate Affairs as we continue to advance once-at-bedtime FT218 for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy," said Greg Divis, Chief Executive Officer of Avadel. "Brandi brings a wealth of corporate affairs experience in the biopharmaceutical industry, which will support the compa
3/14/22 4:30:00 PM ET
$AVDL
Biotechnology: Pharmaceutical Preparations
Health Care

Avadel Pharmaceuticals Shares New LUMRYZ For Extended-Release Oral Suspension Data At SLEEP 2024 June 1-5, 2024

Chat with this insight

Recent Analyst Ratings for $AVDL

$AVDL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Rodman & Renshaw initiated coverage on Avadel Pharmaceuticals with a new price target

Oppenheimer reiterated coverage on Avadel Pharmaceuticals with a new price target

H.C. Wainwright reiterated coverage on Avadel Pharmaceuticals with a new price target

$AVDL Financials

Live finance-specific insights

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12

Avadel Pharmaceuticals to Provide a Corporate Update and Report Second Quarter 2024 Financial Results on August 8

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results

$AVDL Press Releases

Fastest customizable press release news feed in the world

Avadel Pharmaceuticals to Present at the Jefferies London Healthcare Conference

Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12

$AVDL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Palczuk Linda

SEC Form 4 filed by Director Glass Geoffrey Michael

Director Palczuk Linda was granted 11,000 units of Ordinary Shares, increasing direct ownership by 21% to 63,400 units (SEC Form 4)

$AVDL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

Amendment: SEC Form SC 13G/A filed by Avadel Pharmaceuticals plc

$AVDL Market Insights

Live Market Insights

Avadel Pharmaceuticals To Join Russell 3000 Index, Effective At The Open Of Us Equity Markets On Monday, July 1, 2024